GLG News by Physicians who Treat End Stage Renal Disease (ESRD)

The referred trial involves patients of 18-70 years of age who suffered a heart attack previous year. The ingredients of "XZK capsules have not been isolated and studied yet." The capsules contained "a combination of lovastatin, lovastatin hydroxyl acid, ergosterol and other components." Pills were...

The effects attributed to newly invented device are not based on known principles of human physiology and, therefore, will not pass to enroll in clinical trials. Magnets were used in medicine since Hippocrates (460-360BC) for hemorrhage control. Current applications include immunomagnetic cell...

Two studies (ACCORD and ADVANCE) designed to confirm positive effect of tight blood sugar control on the rate of cardiovascular and cerebrovascular events failed to do so. Incidence of hypoglycemia, weight gain and fluid retention, however, was significantly higher in ACCORD trial. Almost half...

Drugs are relatively ineffective for NSCLC due to the following. Firstly, stage III is the main target of chemotherapy, while being very heterogenous combination of T and N criteria. Outcome results, therefore, are controversial. Next, lung cancer is more than many other malignancies is caused by an...

The heart is responsible for maintenance of systemic circulation and, therefore, perfusion of the entire body. Beta blockers protect the heart by decreasing its work and, consequently, compromise systemic circulation. It is not a surprise that the most sensitive to decreased perfusion organ, brain,...

While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these...

This article brings more visibility to issue of effect of angiogenesis inhibitors on kidney function Other mechanisms of injury have previously been described.  Current case simply adds visibility and more definitive evidence of effect in humans Mechanism described is likely not restricted...

1- This analysis adds to the formalized analysis of the safety literature on ESA use in oncology. 2- Its timing will impact on the FDA CDER ODAC meeting scheduled to review Amgen and Ortho Biotech's ESA drugs.

1- Raises the upcoming FDA safety meeting on Injectafer (Ferinject). 2- Issues related to hypophosphatemia and cardiovascular health raised. 3- Quaestion of impact for ferumoxytol (AMAG) and other IV iron drugs.

ESA's under pressure because of FDA black box warning. Ferumoxytol has safety and efficacy data to support NDA. Ease of use will immediately give it access to HD market and will grow   pre ESRD CKD market, as is appropriate.